TOWARD THE DUAL TARGETING OF HER2 AND ANDROGEN RECEPTOR IN PATIENTS WITH HIGH-RISK, HORMONE-NAIVE PROSTATE CANCER WITH CURATIVE INTENT
$362,100FY2022Department of the ArmyDOD
The Geneva Foundation
Investigators
View source on USAspending →TOWARD THE DUAL TARGETING OF HER2 AND ANDROGEN RECEPTOR IN PATIENTS WITH HIGH-RISK, HORMONE-NAIVE PROSTATE CANCER WITH CURATIVE INTENT · GrantIndex